Description
Tirofiban hydrochloride is tirofiban hydrochloride. Tirofiban is an anti-angina drug successfully developed by Merck Company in the United States. It is clinically used in combination with heparin to treat acute coronary syndromes, including patients with unstable angina or non-Q-wave myocardial infarction, and patients undergoing percutaneous transluminal coronary angioplasty (PTCA) or atherectomy. At present, the main drugs in clinical use are tirofiban hydrochloride injection, the trade name is Xinweining, which is a reversible non-peptide platelet surface glycoprotein (GP) IIb/IIIa receptor antagonist, which can competitively inhibit the Binding of fibrinogen to blood Chemicalbook platelet (GP) IIb/IIIa receptors. Intravenous injection, it can dose-dependently inhibit platelet aggregation in vitro caused by ADP, collagen, arachidonic acid, thromboxane analog U46619 and thrombin, prolong bleeding time, and inhibit thrombosis. In healthy volunteers, at the routine recommended dose, the peak plasma concentration is similar to the steady-state plasma concentration during intravenous infusion. T1/2 is 2h. In the dose range of 0.01 ~ 25μg/ml, the PPB of this product is 65%, regardless of concentration. Free drug accounts for 35% of plasma, Vd is 22 ~ 42L. In healthy volunteers, CL was 213-314 ml/min, and renal clearance accounted for 39%-69% of plasma clearance.
Complaint
